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Background: HCV affects >170 million people worldwide and is a leading cause of
liver diseases such as hepatocellular carcinoma. Each year, Pakistan reports hundreds
of cases and now it has become a serious health issue. HCV has two transmembrane
glycoproteins (E1 and E2) that are involved in virus entry through viral attachment,
but because of their hypervariable nature they have become difficult targets for
vaccine development.
Methods: A total of 150 protein sequences of E1 and E2 belonging to genotypes 3a
and 1a were retrieved from the NCBI protein database and were subjected to
conservation and variation analysis using the multiple sequence alignment feature of
the CLC workbench. A consensus sequence of each genotype of E1 and E2 was
obtained and these consensus sequences were further analyzed to construct a
global consensus sequence, which was used to design potentially conserved
peptides.
Results: From the sequence conservation analysis, highly conserved residues were
identified and were used to design peptides. Only two peptides were found to be
conserved in the E1 protein of genotypes 3a and 1a and a total of nine conserved
peptides were designed for the HCV E2 protein of those genotypes. These designed
peptides could serve as useful targets in developing new inhibitory compounds.
Conclusion: This study was designed to perform conservation and variability analysis
of HCV glycoproteins and to find potentially conserved peptides among genotypes
3a and 1a (the most prevalent genotypes in Pakistan) that could serve as useful
targets in the development of novel inhibitory compounds, thus reducing the threat
of HCV infection in Pakistan.
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Chronic infection with hepatitis C virus (HCV) affects >170 million individuals, ap-
proximately 3% of the world population, and is responsible for approximately 350,000
deaths every year [1]. HCV has become a leading cause of liver diseases such as hepa-
tocellular carcinoma. It is a small, single-stranded, positive strand RNA virus encoding
structural and non-structural proteins. It has many genetic variants, an important fac-
tor to consider in drug development. There are six known major genotypes and >100
subtypes of HCV [1,2] and owing to this strain variability, no vaccine has been devel-
oped to date; the currently approved treatment for HCV is pegylated interferon α
(PEG-INF α) in combination with ribavirin and Boceprevir/Telaprevir.© 2013 Idrees et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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become infected. Prevalence analysis has revealed that the most prevalent HCV geno-
type in Pakistan is 3a, except in Balochistan where the most frequent subtype is 1a [3].
Among the HCV structural proteins, the HCV glycoproteins (E1 and E2) are both hy-
pervariable transmembrane are present on the surface of the virus and are extremely
involved in virus attachment with host cell through cell receptors [4,5]. Envelope pro-
tein E1 has a C-terminal domain involved in membrane permeability changes and
membrane association [3]. Envelope protein E2 contains up to 11 N-linked glycosyla-
tion sites and is involved in viral entry by interacting with an extracellular loop of hu-
man CD81, scavenger receptor class B type 1 (SRB-1), high density lipoprotein (HDL)
binding molecule and mannose binding proteins (DC-SIGN and L-SIGN) [6-12]. Both
glycoproteins are important in viral entry but because of their hypervariable nature it is
difficult to design vaccines or inhibitory compounds against them. Therefore, this study
was conducted to perform a sequence analysis of E1 and E2 among genotypes 3a and
1a to determine conserved peptides in HCV that could be useful targets in the design
of novel inhibitory compounds, thus reducing threats of HCV in Pakistan.Results
Global consensus sequence development
To design effective peptides, a consensus-based approach was used. A global consensus
sequence was constructed using the multiple alignment feature of the CLC Workbench
for HCV E1 (Figure 1) and E2 (Figure 2) proteins. The global consensus sequence is
shown at the base of the alignments in Figures 1 and 2.Peptide design
Sequences of HCV E1 and E2 of genotypes 3a and 1a were retrieved from the NCBI
protein database and were subjected to conservation analysis using the multiple se-
quence alignment feature of the CLC workbench. From the highly conserved residues
of E1, short peptides of 8–25 amino acids were designed (Table 1), and from the highly
conserved regions of E2, similarly short peptides were designed using the same criteria
as for E1 (Table 2). These peptides are conserved among the 1a and 3a genotypes, so
they could be useful for designing peptide-based vaccines and inhibitory compounds.Figure 1 Multiple sequence alignment showing global consensus sequence of HCV E1 protein of
genotypes 3a and 1a isolated from different regions of the world. The global consensus sequence is
shown at the bottom of the alignment; identical residues are represented by (.) and ambiguous symbols
are represented by (X).
Figure 2 Multiple sequence alignment showing global consensus sequence of HCV E2 protein of
genotypes 3a and 1a isolated from different regions of the world. The global consensus sequence is
shown at the bottom of the alignment; identical residues are represented by (.) and ambiguous symbols
are represented by (X).
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Phylogenetic trees of both proteins showed clusters built on the basis of evolutionary
relatedness. It can be inferred that envelope proteins of genotype 3a isolated from dif-
ferent regions of the world are evolutionarily related and are also related to 1a from dif-
ferent countries. It can also be inferred that genotypes 1a and 3a share a common
ancestry. Therefore it can be concluded that HCV E1 and E2 are evolutionarily related
to 3a in other countries and are also related to genotype 1a. The evolutionary tree of
E1 protein is shown in Figure 3 and that of HCV E2 protein is shown in Figure 4.Discussion
HCV infection has become a serious health problem worldwide but owing to its six ge-
notypes and more than 100 subtypes it is elusive in vaccine development. HCV has a
9.6kB genome that encodes 10 proteins in the order NH2-Core-E1-E2-p7-NS2-NS3-
NS4A-NS4B-NS5A-NS5B-COOH [2]. Among these proteins, E1 and E2 are involved in
viral entry as they are required for virus attachment to receptors on the host cell.
Therefore these two proteins could serve as useful targets in in the design of novel in-
hibitory compounds. However, because of their hypervariable nature, targeting these
proteins is difficult.
Keeping these points in mind, this study was designed to perform conservation and
variation analysis on both E1 and E2 sequences isolated from different regions of theTable 1 Predicted peptides for HCV E1 conserved in 1a and 3a genotypes




Composition of (Leu, Val,
Ile, Met, Phe, and Trp)
1 209-216 NSSIVYEA 8 882 1280 25%
2 272-279 CSALYVGD 8 827 1400 25%
Table 2 Predicted peptides for HCV E2 conserved in 1a and 3a genotypes
Sr.
No.






(Leu, Val, Ile, Met,
Phe, and Trp)
1 423-430 NRTALNCN 8 905 120 12.5%
2 502-515 SVCGPVYCFTPSPV 14 5.24 1615 22%
3 524-531 GVPTYNWG 8 893 6970 25%
4 587-604 CPTDCFRKHPEATYSRCG 18 2071 1640 6%
5 606-613 GPWLTPRC 8 929 5810 25%
6 615-629 VDYPYRLWHYPCTVN 15 1926 9650 27%
7 648-658 AACNWTRGERC 11 1266 5930 10%
8 689-713 PALSTGLIHLHQNIVDVQYLYGVGS 25 2695 2560 36%
9 729-738 FLLLADARVC 10 1120 120 50%
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3a and 1a were retrieved and studied. These genotypes (3a and 1a) were selected as they
are reported to be the most prevalent in Pakistan. Analyzing these sequences could help
in development of inhibitory compounds with the potential not only to reduce viral titers
but also contribute to reducing the threat of HCV in the Pakistani population. In-silico
analysis of both glycoproteins revealed conserved and variable regions. From the highly
conserved regions of both proteins, conserved peptides were designed that could poten-
tially serve as targets for vaccine or inhibitory compound development.
Moreover, phylogenetic analysis was conducted to find the evolutionary relationship
between the HCV E1 and E2 genotype 3a of Pakistani origin and E1 and E2 sequences
of genotypes 3a and 1a. In the case of E1 protein, genotype 1a appeared at the root of
the tree and it can be inferred that genotype 3a has evolved from it. In the case of E2
protein, genotype 3a appeared at the root of the tree and it can be inferred that geno-
type 1a has evolved from it. The HCV envelope proteins (E1/E2) in Pakistan are highly
evolutionarily related to 1a and 3a from other countries.Conclusion
Genotype 3a is reported as the most prevalent genotype in Pakistan except in Balochi-
stan where the most prevalent genotype is 1a. This study was designed to identify poten-
tially conserved peptides in the two hypervariable proteins, E1 and E2, of HCV. From
the conservation analysis, highly conserved and variable regions were revealed and from
the highly conserved regions peptides were designed that could serve as useful targets
for developing novel inhibitory compounds against both 3a and 1a genotypes, poten-
tially protecting the Pakistani population against the threat of HCV infection.Methods
Global consensus sequence development
A total of 150 HCV E1 and E2 sequences belonging to genotypes 3a and 1a were re-
trieved from the NCBI protein database. Consensus sequences of E1 and E2 proteins
for each genotype were constructed using the multiple sequence analysis feature of the
CLC workbench. These consensus sequences were further used to construct global
consensus sequences for E1 and E2.
Figure 3 Phylogenetic tree showing evolutionary relationships among HCV E1 proteins of genotype
3a with genotype 1a isolated from different regions of the world.
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Figure 4 Phylogenetic tree showing evolutionary relationships among HCV E2 proteins of genotype
3a with genotype 1a isolated from different regions of the world.
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The consensus sequences of E1 belonging to genotypes 3a and 1a were aligned to identify
the global consensus sequence of E1 in Pakistan and other countries. A global consensus
sequence for E2 protein was found using the same strategy. These global consensus se-
quences could help in designing effective conserved peptides against genotypes 3a and 1a.
Short peptide sequences were derived from the highly conserved regions of HCV E1 and
E2. As the HCV glycoproteins are highly variable and are required for viral entry, it is im-
portant to identify conserved peptides that could serve as the best targets for potential in-
hibitors and vaccines. In designing peptides for successful antibody production, many
factors were considered. These included amino acid composition and peptide length,
which can influence correct assembly, purification, and subsequent solubilization. (1) The
peptide length criterion was set at 8–25. Typically, a 10–15 residue length is used for rais-
ing antisera. (2) The hydrophobic amino acid content (Leu, Val, Ile, Met, Phe, and Trp)
was not allowed to exceed 50% in the designed peptide. Conserved peptides were
designed from the global consensus sequence while considering all these factors.
Idrees et al. Theoretical Biology and Medical Modelling 2013, 10:24 Page 7 of 7
http://www.tbiomed.com/content/10/1/24Phylogenetic analysis
HCV E1 and E2 sequences from all over the world were analyzed to establish their evo-
lutionary relationships using the CLC workbench. The phylogenetic analysis feature of
the workbench was used to construct phylogenetic trees for E1 and E2 proteins using
the neighbor-joining method with a bootstrap value of 100.
Future directions
In future, we aim to analyze these peptides further to indicate methods for blocking
HCV entry.
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